A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
Canada will get generic versions of the weight loss drug starting next year, all because the Danish pharmaceutical giant didn't pay a patent maintenance fee
Canada will get generic versions of the weight loss drug starting next year, all because the Danish pharmaceutical giant didn't pay a patent maintenance fee
